{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:52:13Z","timestamp":1792047133595,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,12]]},"DOI":"10.7759\/cureus.99081","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T06:19:17Z","timestamp":1765606757000},"source":"Crossref","is-referenced-by-count":2,"title":["Adverse Effects and Withdrawal Symptoms of Prolonged Glucocorticoid Therapy in Chronic Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Lincoln Xavier","family":"Naranjo Palacio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin Kerime","family":"Rojas L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan Nicol\u00e1s","family":"Forero V\u00e1squez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n Alejandro","family":"\u00c1vila Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian Eduardo","family":"Bedoya Jaramillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayra Nayeli","family":"Estrada Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Eduardo","family":"Escand\u00f3n Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray M","year":"2016","unstructured":"Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016, 15:457-65. 10.1517\/14740338.2016.1140743","journal-title":"Expert Opin Drug Saf"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice JB","year":"2017","unstructured":"Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017, 39:2216-29. 10.1016\/j.clinthera.2017.09.011","journal-title":"Clin Ther"},{"key":"ref3","article-title":"Side effects of longterm oral corticosteroid therapy [Article in French]","volume":"71","author":"Doumeizel PM","year":"2021","unstructured":"Doumeizel PM, Robin F, Ballerie A, et al.. Side effects of longterm oral corticosteroid therapy [Article in French]. Rev Prat. 2021, 71:587-96.","journal-title":"Rev Prat"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5114\/reum\/170845","article-title":"The dichotomy of glucocorticosteroid treatment in immune-inflammatory rheumatic diseases: an evidence-based perspective and insights from clinical practice","volume":"61","author":"Hysa E","year":"2023","unstructured":"Hysa E, Vojinovic T, Gotelli E, et al.. The dichotomy of glucocorticosteroid treatment in immune-inflammatory rheumatic diseases: an evidence-based perspective and insights from clinical practice. Reumatologia. 2023, 61:283-93. 10.5114\/reum\/170845","journal-title":"Reumatologia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2022.101793","article-title":"Risk for osteoporosis and fracture with glucocorticoids","volume":"36","author":"Urquiaga M","year":"2022","unstructured":"Urquiaga M, Saag KG. Risk for osteoporosis and fracture with glucocorticoids. Best Pract Res Clin Rheumatol. 2022, 36:101793. 10.1016\/j.berh.2022.101793","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1788035","article-title":"Safely withdrawing glucocorticoid therapy: a case-based approach","volume":"7","author":"Alenazi M","year":"2024","unstructured":"Alenazi M, Aldahmani K, Imran SA. Safely withdrawing glucocorticoid therapy: a case-based approach. J Diabetes Endocrinol Practice. 2024, 7:129-34. 10.1055\/s-0044-1788035","journal-title":"J Diabetes Endocrinol Practice"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1187100","article-title":"The role of glucocorticoids in increasing cardiovascular risk","volume":"10","author":"Deng HW","year":"2023","unstructured":"Deng HW, Mei WY, Xu Q, et al.. The role of glucocorticoids in increasing cardiovascular risk. Front Cardiovasc Med. 2023, 10:1187100. 10.3389\/fcvm.2023.1187100","journal-title":"Front Cardiovasc Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.52140","article-title":"Glucocorticoid-induced adrenal suppression: physiological basis and strategies for glucocorticoid weaning","volume":"219","author":"Torpy DJ","year":"2023","unstructured":"Torpy DJ, Lim WT. Glucocorticoid-induced adrenal suppression: physiological basis and strategies for glucocorticoid weaning. Med J Aust. 2023, 219:444-7. 10.5694\/mja2.52140","journal-title":"Med J Aust"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/87551225221116266","article-title":"Complications of corticosteroid therapy: a comprehensive literature review","volume":"38","author":"Koshi EJ","year":"2022","unstructured":"Koshi EJ, Young K, Mostales JC, Vo KB, Burgess LP. Complications of corticosteroid therapy: a comprehensive literature review. J Pharm Technol. 2022, 38:360-7. 10.1177\/87551225221116266","journal-title":"J Pharm Technol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1380","article-title":"Glucocorticoid induced adrenal insufficiency","volume":"374","author":"Prete A","year":"2021","unstructured":"Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. BMJ. 2021, 374:n1380. 10.1136\/bmj.n1380","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.61841\/jhkrgs83","article-title":"The analysis study of safety and long-term effects of glucocorticoids in treatment of inflammatory rheumatic disease: a comprehensive systematic review","volume":"10","author":"Rahman FF","year":"2024","unstructured":"Rahman FF, Istiana S. The analysis study of safety and long-term effects of glucocorticoids in treatment of inflammatory rheumatic disease: a comprehensive systematic review. J Adv Med Med Res. 2024, 10:6-15. 10.61841\/jhkrgs83","journal-title":"J Adv Med Med Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000804","article-title":"Glucocorticoid withdrawal syndrome: what to expect and how to manage","volume":"30","author":"Theiler-Schwetz V","year":"2023","unstructured":"Theiler-Schwetz V, Prete A. Glucocorticoid withdrawal syndrome: what to expect and how to manage. Curr Opin Endocrinol Diabetes Obes. 2023, 30:167-74. 10.1097\/MED.0000000000000804","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3904\/kjm.2025.100.4.158","article-title":"Managing adverse effects associated with long-term glucocorticoid use","volume":"100","author":"Kim MK","year":"2025","unstructured":"Kim MK. Managing adverse effects associated with long-term glucocorticoid use. Korean J Biol Sci. 2025, 100:158-65. 10.3904\/kjm.2025.100.4.158","journal-title":"Korean J Biol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5195\/jmla.2020.739","article-title":"A comparison of patient, intervention, comparison, outcome (PICO) to a new, alternative clinical question framework for search skills, search results, and self-efficacy: a randomized controlled trial","volume":"108","author":"Kloda LA","year":"2020","unstructured":"Kloda LA, Boruff JT, Cavalcante AS. A comparison of patient, intervention, comparison, outcome (PICO) to a new, alternative clinical question framework for search skills, search results, and self-efficacy: a randomized controlled trial. J Med Libr Assoc. 2020, 108:185-94. 10.5195\/jmla.2020.739","journal-title":"J Med Libr Assoc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010606","article-title":"Conflicts of interest and spin in reviews of psychological therapies: a systematic review","volume":"6","author":"Lieb K","year":"2016","unstructured":"Lieb K, von der Osten-Sacken J, Stoffers-Winterling J, Reiss N, Barth J. Conflicts of interest and spin in reviews of psychological therapies: a systematic review. BMJ Open. 2016, 6:e010606. 10.1136\/bmjopen-2015-010606","journal-title":"BMJ Open"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/jep.12884","article-title":"Improving the usefulness of a tool for appraising the quality of qualitative, quantitative and mixed methods studies, the Mixed Methods Appraisal Tool (MMAT)","volume":"24","author":"Hong QN","year":"2018","unstructured":"Hong QN, Gonzalez-Reyes A, Pluye P. Improving the usefulness of a tool for appraising the quality of qualitative, quantitative and mixed methods studies, the Mixed Methods Appraisal Tool (MMAT). J Eval Clin Pract. 2018, 24:459-67. 10.1111\/jep.12884","journal-title":"J Eval Clin Pract"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-015-0066-7","article-title":"Automating data extraction in systematic reviews: a systematic review","volume":"4","author":"Jonnalagadda SR","year":"2015","unstructured":"Jonnalagadda SR, Goyal P, Huffman MD. Automating data extraction in systematic reviews: a systematic review. Syst Rev. 2015, 4:78. 10.1186\/s13643-015-0066-7","journal-title":"Syst Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226620","article-title":"Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo- controlled, double-blind trial","volume":"84","author":"Ruyssen-Witrand A","year":"2025","unstructured":"Ruyssen-Witrand A, Brusq C, Masson M, et al.. Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo- controlled, double-blind trial. Ann Rheum Dis. 2025, 84:49-59. 10.1136\/ard-2024-226620","journal-title":"Ann Rheum Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11733","article-title":"The burden of glucocorticoids: patterns of use, adverse health conditions, and health care use in two cohorts with systemic lupus erythematosus","volume":"6","author":"Katz P","year":"2024","unstructured":"Katz P, Pedro S, Park J, Choi J, Michaud K. The burden of glucocorticoids: patterns of use, adverse health conditions, and health care use in two cohorts with systemic lupus erythematosus. ACR Open Rheumatol. 2024, 6:918-26. 10.1002\/acr2.11733","journal-title":"ACR Open Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225369","article-title":"Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study","volume":"83","author":"Katsumata Y","year":"2024","unstructured":"Katsumata Y, Inoue E, Harigai M, et al.. Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study. Ann Rheum Dis. 2024, 83:998-1005. 10.1136\/ard-2023-225369","journal-title":"Ann Rheum Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42371-z","article-title":"Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib","volume":"13","author":"Spinelli FR","year":"2023","unstructured":"Spinelli FR, Garufi C, Mancuso S, Ceccarelli F, Truglia S, Conti F. Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib. Sci Rep. 2023, 13:15537. 10.1038\/s41598-023-42371-z","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.456","article-title":"POS0460 impact of maintenance therapy with low-dose glucocorticoids in patients undergoing biological and targeted synthesis DMARDS for rheumatoid arthtristis","volume":"82","author":"Giollo A","year":"2023","unstructured":"Giollo A, Zen M, Salvato M, et al.. POS0460 impact of maintenance therapy with low-dose glucocorticoids in patients undergoing biological and targeted synthesis DMARDS for rheumatoid arthtristis. Ann Rheum Dis. 2023, 82:487-8. 10.1136\/annrheumdis-2023-eular.456","journal-title":"Ann Rheum Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223977","article-title":"Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial","volume":"82","author":"Almayali AA","year":"2023","unstructured":"Almayali AA, Boers M, Hartman L, et al.. Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial. Ann Rheum Dis. 2023, 82:1307-14. 10.1136\/ard-2023-223977","journal-title":"Ann Rheum Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002701","article-title":"Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study","volume":"8","author":"Floris A","year":"2022","unstructured":"Floris A, Chessa E, Sebastiani GD, et al.. Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study. RMD Open. 2022, 8:002701. 10.1136\/rmdopen-2022-002701","journal-title":"RMD Open"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.2505","article-title":"Pos0540 clinical outcomes associated with glucocorticoid discontinuation among patients with rheumatoid arthritis receiving upadacitinib or adalimumab","volume":"81","author":"Fleischmann R","year":"2022","unstructured":"Fleischmann R, Combe B, Ostor A, et al.. Pos0540 clinical outcomes associated with glucocorticoid discontinuation among patients with rheumatoid arthritis receiving upadacitinib or adalimumab. Ann Rheum Dis. 2022, 81:533. 10.1136\/annrheumdis-2022-eular.2505","journal-title":"Ann Rheum Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.698","article-title":"OP0263 favorable balance of benefit and harm of long-term, low-dose prednisolone added to standard treatment in rheumatoid arthritis patients aged 65+: the pragmatic, multicenter, placebo-controlled GLORIA Trial","volume":"81","author":"Boers M","year":"2022","unstructured":"Boers M, Hartman L, Opris-Belinski D, et al.. OP0263 favorable balance of benefit and harm of long-term, low-dose prednisolone added to standard treatment in rheumatoid arthritis patients aged 65+: the pragmatic, multicenter, placebo-controlled GLORIA Trial. Ann Rheum Dis. 2022, 81:174-5. 10.1136\/annrheumdis-2022-eular.698","journal-title":"Ann Rheum Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11267","article-title":"Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus","volume":"3","author":"Tselios K","year":"2021","unstructured":"Tselios K, Gladman DD, Su J, Urowitz MB. Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus. ACR Open Rheumatol. 2021, 3:550-7. 10.1002\/acr2.11267","journal-title":"ACR Open Rheumatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae077","article-title":"Very-low-dose glucocorticoid therapy in rheumatoid arthritis: impact of b\/tsDMARDs initiation timing on glucocorticoid withdrawal","volume":"64","author":"Giollo A","year":"2025","unstructured":"Giollo A, Salvato M, Frizzera F, Zen M, Doria A. Very-low-dose glucocorticoid therapy in rheumatoid arthritis: impact of b\/tsDMARDs initiation timing on glucocorticoid withdrawal. Rheumatology (Oxford). 2025, 64:501-8. 10.1093\/rheumatology\/keae077","journal-title":"Rheumatology (Oxford)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.663","article-title":"OP0270 tapering of long-term, low-dose glucocorticoids in senior rheumatoid arthritis patients: follow-up of the pragmatic, multicentre, placebo-controlled GLORIA trial","volume":"81","author":"Almayali A","year":"2022","unstructured":"Almayali A, Boers M, Hartman L, et al.. OP0270 tapering of long-term, low-dose glucocorticoids in senior rheumatoid arthritis patients: follow-up of the pragmatic, multicentre, placebo-controlled GLORIA trial. Ann Rheum Dis. 2022, 81:180. 10.1136\/annrheumdis-2022-eular.663","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/442943-adverse-effects-and-withdrawal-symptoms-of-prolonged-glucocorticoid-therapy-in-chronic-rheumatoid-arthritis-and-systemic-lupus-erythematosus-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T06:19:17Z","timestamp":1765606757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/442943-adverse-effects-and-withdrawal-symptoms-of-prolonged-glucocorticoid-therapy-in-chronic-rheumatoid-arthritis-and-systemic-lupus-erythematosus-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.99081","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,12]]}}}